The ABC's of Carcinoid and Neuroendocrine Tumors

Three of the world’s leading carcinoid and NET cancer specialists – Dr. Richard R.P. Warner, Dr. Edward M. Wolin, and Dr. Eugene A. Woltering  – talk about the advice they offer their patients, the advances they have seen during their careers, and what they anticipate will be available for NET patients in the future. (Click on the words YouTube in the bottom right of the video to see it in a larger size).

The Latest News

Trader Joe’s Saved My Life: Steven Muller’s Story

The combination of a lengthy road-bike ride, a recovery drink mix, and dried figs from Trader Joe’s led to a health crisis for Steven Muller and a subsequent diagnosis of a neuroendocrine tumor (NET) in his small intestine. Neuroendocrine tumors, including carcinoid cancer, pancreatic neuroendocrine tumors, pheochromocytoma and multiple endocrine neoplasia (MEN) are rare diseases that affect at least 125,000 people in the United States. Steven is sharing his story beginning on February 29, 2016, Rare Disease Day, in hopes that others who have neuroendocrine tumors get a proper diagnosis, early on.  Read more

CCF and Self Care Catalysts Provide Free Digital Patient App for Neuroendocrine Tumor Patients, Sponsored in Part by Ipsen Biopharmaceuticals, Inc.

Ipsen Biopharmaceuticals has partnered with the Carcinoid Cancer Foundation and Self Care Catalysts to provide a digital patient support tool known as the Carcinoid NETs Health Storylines mobile and web application. Sponsored in part by Ipsen, the free app is designed to empower, engage, educate and motivate carcinoid and NET patients who are newly-diagnosed or undergoing treatment or surveillance to take control of their disease. Read more and download the app: http://prn.to/1SbHEne

Advanced Accelerator Applications Announces Expanded Access Program for PRRT and New Drug Application

Advanced Accelerator Applications (AAA) has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program Lutathera is being made available to patients with “inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy.” Read more

Lexicon Pharmaceuticals Submits New Drug Application for Telotristat Etiprate

Lexicon Pharmaceuticals has submitted a new drug application to the US Food and Drug Administration (FDA) for Telotristat Etiprate for the treatment of  carcinoid syndrome. Read more